

Annual Conference Brings Together Remarkable Team of Pre-eminent Medical and Research Professionals to Cure Rare Cancer.

SALT LAKE CITY, UT, USA, December 6, 2017 /EINPresswire.com/ -- The Cholangiocarcinoma Foundation (CCF) will host its 5th [Annual Conference](#) on January 31 to February 2, 2018 at the City Creek Marriott in downtown Salt Lake City. This conference will be the largest single gathering of medical and research professionals, industry, policy makers, patients, caregivers and other global stakeholders with the sole focus of curing bile duct cancer. More than 40 sessions featuring 28 internationally renowned speakers will present topics in basic, translational and clinical research from the bench-to-bedside perspective. First-time faculty will include representatives from the Food and Drug Administration (FDA), National Institutes of Health (NIH) and Patient Centered Outcomes Research Institute (PCORI). Since the inaugural Conference in 2014, attendance has doubled each year. Based on this extraordinary success, we anticipate hosting more than 350 individuals from 15 countries.



Dr. Kelley

The 2018 Conference Chairs are Nabeel Bardeesy, PhD - Associate Professor of Medicine at Harvard Medical School and the Massachusetts General Hospital Cancer Center; and R. Kate (Katie) Kelley, MD - Associate Professor of Clinical Medicine at the University of California San Francisco.

“

The conference will foster collaborations, relationships, and invigorate a community of scientists, healthcare providers, and patients all working to make great progress against this difficult cancer.”

*Katie Kelley, UCSF,
Conference Chair*

Our generous Sponsors include: ASLAN Pharmaceuticals, Incyte, Shire, Taiho Oncology, Agios, Leap Therapeutics, RedHill Biopharma, Bristol-Myers Squibb, NuCana, Boston Scientific, Conquer Cancer Foundation, Promotion in Motion.

Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further research. An Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI) will make it possible for 30 patients to attend and participate in all aspects of the Conference.

Programming will also include an Industry Forum, Poster Session, Patient Engagement Roundtables and Exhibit Hall.

View the [agenda](#).

[About the Cholangiocarcinoma Foundation](#) (CCF)

Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by

cholangiocarcinoma (bile duct cancer).

About Cholangiocarcinoma

Cholangiocarcinoma is a “silent” form of cancer that originates from the cells lining the bile ducts. It is classified as a heterogeneous group of three anatomically distinct cancers grouped according to the location from which they arise: within the bile ducts (intrahepatic), outside the bile ducts (extrahepatic), and in between where the bile ducts exit the liver (perihilar).

The incidence and mortality of cholangiocarcinoma in North America and Europe has increased dramatically in the past few decades. In the US, there are approximately 6,000 new cases diagnosed each year. Because patients commonly present with symptoms that mimic those of other ailments, and there is no validated method of early detection, the majority of patients are diagnosed when the cancer is far too advanced to be removed by surgery. In these cases, chemotherapy and radiation therapy are the mainstay of treatment. The 5-year survival rate for intrahepatic cholangiocarcinoma is estimated at 2-15%.



Jordan Giles
Cholangiocarcinoma Foundation
888-396-6731x10
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.